Former Merrill Lynch banker David Bottomley says he first became aware of the premiums global medical device firms were willing to pay for Australian science while overseeing a string of healthcare deals two decades ago.
Despite the success of stand-outs like hearing implant maker Cochlear, medical technology, or medtech, is a notoriously complex sector and struggles to attract the same level of funding as the biotech industry, where the returns are far higher, but so are the risks of failure.
Loading…